NIPRADILOL

Details

Stereochemistry	UNKNOWN
Molecular Formula	C15H22N2O6
Molecular Weight	326.345
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NCC(O)COC1=C2OCC(CC2=CC=C1)O[N+]([O-])=O

InChI

InChIKey=OMCPLEZZPVJJIS-UHFFFAOYSA-N

InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C15H22N2O6
Molecular Weight	326.345
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1917
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/11937782

Nipradilol is a beta blocker and nitric oxide donor. It was launched in Japan in 1988. This medicine lowers intraocular pressure by suppressing aqueous production and increasing fluid drainage from the eye. It is usually used to treat glaucoma and intraocular hypertension. The most commonly reported adverse reactions include conjunctival congestion, superficial keratitis, eye irritation, bloodshot eyes, itch and headache. If any of these symptoms occur, consult with your doctor or pharmacist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11937782	Antagonist 2849
Adrenergic receptor alpha-1 171 Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11937782	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1917	Primary		Approved 8583	Unknown Approved Use Unknown
Ocular hypertension 52 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1917	Primary		Approved 8583	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
6.07 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
5.72 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
8.43 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
16.63 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
12.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11.19 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
47.32 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
31.12 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
73.89 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
195.93 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
169.89 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
217.11 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
4.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	NIPRADILOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
8.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18370546/	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DENITRONIPRADILOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
0.25 % 2 times / day multiple, ophthalmic Recommended Dose: 0.25 %, 2 times / day Route: ophthalmic Route: multiple Dose: 0.25 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17220049/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17220049/	Sources: https://pubmed.ncbi.nlm.nih.gov/17220049/
6 mg 2 times / day multiple, oral Studied dose Dose: 6 mg, 2 times / day Route: oral Route: multiple Dose: 6 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/	Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (grade 2, 1.4%) Nausea (grade 2, 1.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/

AEs

AE	Significance	Dose	Population
Headache	grade 2, 1.4% Disc. AE	6 mg 2 times / day multiple, oral Studied dose Dose: 6 mg, 2 times / day Route: oral Route: multiple Dose: 6 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/
Nausea	grade 2, 1.4% Disc. AE	6 mg 2 times / day multiple, oral Studied dose Dose: 6 mg, 2 times / day Route: oral Route: multiple Dose: 6 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8565030/

PubMed

Title	Date	PubMed
Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo.	2008-08	18696344

Patents

Sample Use Guides

In Vivo Use Guide

1 drop at a time, twice a day.

Route of Administration: Other

In Vitro Use Guide

Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro. Nipradilol protects RGCs from apoptosis

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:25 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:25 GMT 2025`
Record UNII	FVM336I71Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYPADIL

Preferred Name

English

NIPRADILOL

Official Name

English

nipradilol [INN]

Common Name

English

Nipradolol [WHO-DD]

Common Name

English

NIPRADOLOL

Common Name

English

8-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)-3-CHROMANOL, 3-NITRATE

Common Name

English

NIPRADILOL [MI]

Common Name

English

NIPRADILOL [MART.]

Common Name

English

NIPRADILOL [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576